Counting unit: one existing catalog study per card. The candidates and conditions differ; no pooled success rate is calculated.
Result: antibacterial activity and clearance in reported mouse infection experiments.
AI contribution: learned structure–activity screening selected an existing compound.
Test and comparison: bacterial assays, mouse infection models, and a laboratory resistance comparison with ciprofloxacin.
Limit: the source planned further development for humans; mouse efficacy does not establish patient benefit.
Original MIT report · 20 Feb 2020
Result: targeted activity against A. baumannii and treatment of mouse wound infections.
AI contribution: ranked compounds for experimental selection.
Test and comparison: activity against resistant isolates; little activity against other bacterial species in the reported assays.
Limit: narrow-spectrum activity is a property in these experiments, not demonstrated clinical safety or efficacy.
Original MIT report · 25 May 2023
Result: six of 58 synthesized compounds killed a resistant A. baumannii strain in laboratory tests.
AI contribution: generated molecules and synthesis recipes.
Test and comparison: antibacterial assays; two compounds underwent mouse toxicity testing. Four others were not water-soluble.
Limit: toxicity testing is not an infected-animal efficacy experiment. The source describes that as a next step; mechanism remained unresolved.
Original Stanford report · 28 Mar 2024
Result: NG1 activity in a mouse gonorrhea model and DN1 clearance of MRSA skin infection in mice.
AI contribution: fragment-based and unconstrained molecular generation, followed by computational screening.
Test and comparison: synthesis and bacterial assays followed by separate pathogen-specific infection models.
Limit: only two of 80 selected fragment candidates could be synthesized. Further preclinical optimization was underway; these reports do not demonstrate human benefit.
Original MIT report · 14 Aug 2025